Ratings by UBS (Colin Bristow)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/1/2026 | Nanobiotix S.A | NBTX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2025 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 7/21/2025 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 5/21/2025 | ALX Oncology | ALXO | Maintain | Buy (Buy) |
|
Details | ||
| 5/2/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/30/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/22/2025 | Immunovant | IMVT | Downgrade | Neutral (Buy) |
14.46 (44.87) |
210.3% | Details | |
| 4/14/2025 | Amgen | AMGN | Maintain | Neutral (Neutral) |
|
Details | ||
| 4/8/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 3/28/2025 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (Buy) |
|
Details | ||
| 3/3/2025 | C4 Therapeutics | CCCC | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/14/2025 | C4 Therapeutics | CCCC | Downgrade | Neutral (Buy) |
3.20 (3.99) |
24.69% | Details | |
| 2/11/2025 | Vertex | VRTX | Maintain | Buy (Buy) |
|
Details | ||
| 2/5/2025 | Pfizer | PFE | Maintain | Neutral (Neutral) |
|
Details | ||
| 2/5/2025 | Merck | MRK | Maintain | Buy (Buy) |
|
Details | ||
| 1/27/2025 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 1/8/2025 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/8/2025 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2024 | PTC Therapeutics | PTCT | Maintain | Buy (N/A) |
|
Details | ||
| 11/5/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 10/31/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/17/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/9/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 8/26/2024 | PTC Therapeutics | PTCT | Upgrade | Buy (Neutral) |
34.15 (70.96) |
107.79% | Details | |
| 8/16/2024 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2024 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (N/A) |
|
Details | ||
| 8/13/2024 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2024 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 8/2/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2024 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/12/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/12/2024 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/12/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 6/10/2024 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 5/7/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/3/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/17/2024 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2024 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/17/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/13/2024 | BioXcel Therapeutics | BTAI | Maintain | Neutral (N/A) |
|
Details | ||
| 3/13/2024 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2024 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2024 | C4 Therapeutics | CCCC | Maintain | Buy (N/A) |
|
Details | ||
| 2/21/2024 | BioXcel Therapeutics | BTAI | Downgrade | Neutral (Buy) |
3.51 (0.84) |
-76.07% | Details | |
| 2/16/2024 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/8/2024 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/6/2024 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2024 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/2/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2024 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/29/2024 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2024 | Biogen | BIIB | Downgrade | Neutral (Buy) |
251.68 (174.63) |
-30.61% | Details | |
| 1/17/2024 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/17/2024 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 12/14/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 12/1/2023 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 11/2/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/30/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/20/2023 | Pfizer | PFE | New Coverage | Neutral (N/A) |
31.41 (25.17) |
-19.87% | Details | |
| 10/13/2023 | Immunovant | IMVT | Upgrade | Buy (Neutral) |
36.64 (44.87) |
22.46% | Details | |
| 10/10/2023 | Nanobiotix S.A | NBTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2023 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 8/16/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (N/A) |
|
Details | ||
| 8/8/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/8/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 8/4/2023 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/4/2023 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 8/2/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 7/27/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2023 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/24/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/21/2023 | C4 Therapeutics | CCCC | Maintain | Buy (N/A) |
|
Details | ||
| 5/25/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/24/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 5/18/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 5/15/2023 | Sarepta Therapeutics | SRPT | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 5/2/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/2/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 5/1/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/26/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/25/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 4/25/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 4/25/2023 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 4/25/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2023 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/21/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/21/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2023 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2023 | ALX Oncology | ALXO | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | C4 Therapeutics | CCCC | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2023 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/15/2023 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/8/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/6/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 2/6/2023 | Immunovant | IMVT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/2/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2023 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 1/31/2023 | Merck | MRK | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2023 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2023 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/30/2023 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 1/30/2023 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 1/26/2023 | Pfizer | PFE | Downgrade | Neutral (Buy) |
44.71 (28.30) |
-36.7% | Details | |
| 12/16/2022 | Sarepta Therapeutics | SRPT | Upgrade | Buy (Neutral) |
124.65 (19.54) |
-84.32% | Details | |
| 12/15/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2022 | Candel Therapeutics Inc. | CADL | Maintain | Buy (N/A) |
|
Details | ||
| 12/9/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/8/2022 | Omeros Corp. | OMER | Downgrade | Neutral (Buy) |
2.22 (18.95) |
753.6% | Details | |
| 11/7/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/4/2022 | C4 Therapeutics | CCCC | Maintain | Buy (N/A) |
|
Details | ||
| 10/27/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 10/26/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/21/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 10/21/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/20/2022 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 10/19/2022 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/6/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 9/28/2022 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (N/A) |
|
Details | ||
| 9/28/2022 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 9/26/2022 | Immunovant | IMVT | Downgrade | Neutral (Buy) |
5.13 (44.87) |
774.66% | Details | |
| 8/17/2022 | Acumen Pharmaceuticals, Inc. | ABOS | Maintain | Buy (N/A) |
|
Details | ||
| 7/28/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 7/18/2022 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2022 | Immunovant | IMVT | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2022 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2022 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/18/2022 | C4 Therapeutics | CCCC | Maintain | Buy (N/A) |
|
Details | ||
| 4/13/2022 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/7/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2022 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 2/16/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 2/8/2022 | Amgen | AMGN | New Coverage | Neutral (N/A) |
223.53 (320.72) |
43.48% | Details | |
| 12/17/2021 | Candel Therapeutics Inc. | CADL | Maintain | Buy (N/A) |
|
Details | ||
| 12/13/2021 | Merck | MRK | Downgrade | Neutral (Buy) |
72.86 (153.39) |
110.53% | Details | |
| 12/13/2021 | Pfizer | PFE | Upgrade | Buy (Neutral) |
52.08 (28.30) |
-45.66% | Details | |
| 11/29/2021 | Bristol-Myers Squibb Co. | BMY | Maintain | Neutral (N/A) |
|
Details | ||
| 11/11/2021 | Omeros Corp. | OMER | Maintain | Buy (N/A) |
|
Details | ||
| 10/20/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/15/2021 | Omeros Corp. | OMER | Maintain | Buy (N/A) |
|
Details | ||
| 9/16/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 8/31/2021 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/23/2021 | Candel Therapeutics Inc. | CADL | New Coverage | Buy (N/A) |
6.30 (12.86) |
104.13% | Details | |
| 7/30/2021 | Molecular Templates | MTEM | Maintain | Neutral (N/A) |
|
Details | ||
| 6/29/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 6/10/2021 | Biogen | BIIB | Upgrade | Buy (Neutral) |
406.94 (217.20) |
-46.63% | Details | |
| 5/28/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2021 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 4/29/2021 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 4/26/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 4/6/2021 | ALX Oncology | ALXO | New Coverage | Buy (N/A) |
74.18 (2.13) |
-97.13% | Details | |
| 2/1/2021 | Omeros Corp. | OMER | New Coverage | Buy (N/A) |
19.46 (18.95) |
-2.62% | Details | |
| 2/1/2021 | Molecular Templates | MTEM | New Coverage | Neutral (N/A) |
11.45 (0.11) |
-99.04% | Details | |
| 2/1/2021 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
46.32 (0.84) |
-98.19% | Details | |
| 1/11/2021 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Buy) |
82.29 (19.54) |
-76.25% | Details | |
| 11/20/2020 | Vertex | VRTX | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2020 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2020 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
59.96 (118.30) |
97.3% | Details | |
| 10/28/2020 | Biogen | BIIB | New Coverage | Neutral (N/A) |
256.76 (406.94) |
58.49% | Details | |
| 10/28/2020 | Amgen | AMGN | New Coverage | Neutral (N/A) |
224.89 (438.21) |
94.86% | Details | |
| 10/28/2020 | Alexion Pharmaceuticals | ALXN | New Coverage | Neutral (N/A) |
120.76 (182.01) |
50.72% | Details | |
| 10/28/2020 | PTC Therapeutics | PTCT | New Coverage | Neutral (N/A) |
51.95 (70.96) |
36.59% | Details | |
| 10/28/2020 | Vertex | VRTX | New Coverage | Buy (N/A) |
207.15 (551.09) |
166.03% | Details | |
| 10/28/2020 | Immunovant | IMVT | New Coverage | Buy (N/A) |
41.89 (44.87) |
7.11% | Details | |
| 10/28/2020 | Sarepta Therapeutics | SRPT | New Coverage | Buy (N/A) |
138.62 (19.54) |
-85.9% | Details | |
| 10/28/2020 | Clarivate Analytics | CCC | New Coverage | Buy (N/A) |
29.50 (7.48) |
-74.64% | Details |
